| Literature DB >> 22645474 |
Amir M Ramezani1, Jamshid L Manzoori, Mohammad Amjadi, Abolghasem Jouyban.
Abstract
A spectrofluorimetric method is proposed for the determination of human serum albumin (HSA) and bovine serum albumin (BSA) using terbium-danofloxacin (Tb(3+)-Dano) as a fluorescent probe. These proteins remarkably enhance the fluorescence intensity of the Tb(3+)-Dano complex at 545 nm, and the enhanced fluorescence intensity of Tb(3+)-Dano is proportional to the concentration of proteins (HSA and BSA). Optimum conditions for the determination of HSA were investigated and found that the maximum response was observed at: pH = 7.8, [Tb(3+)] = 8.5 × 10(-5) mol L(-1), [Dano] = 1.5 × 10(-4) mol L(-1). The calibration graphs for standard solutions of BSA, HSA, and plasma samples of HSA were linear in the range of 0.2 × 10(-6) - 1.3 × 10(-6) mol L(-1), 0.2 × 10(-6) - 1.4 × 10(-6) mol L(-1), and 0.2 × 10(-6) - 1 × 10(-6) mol L(-1), respectively. The detection limits (S/N = 3) for BSA, HSA, and plasma sample of HSA were 8.7 × 10(-8) mol L(-1), 6.2 × 10(-8) mol L(-1), and 8.1 × 10(-8) mol L(-1), respectively. The applicability of the method was checked using a number of real biological plasma samples and was compared with the UV spectrometric reference method. The results was showed that the method could be regarded as a simple, practical, and sensitive alternative method for determination of albumin in biological samples.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22645474 PMCID: PMC3354745 DOI: 10.1100/2012/940541
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Excitation and emission spectra. (a): Excitation spectra (b): Emission spectra. (1) Tb3+, (2) BSA, (3) HSA, (4) Tb3+-BSA, (5) Tb3+-HSA, (6) Tb3+-Dano, (7) Tb3+-Dano-BSA, (8) Tb3+-Dano-HSA, (9) Tb3+-Dano-HSA (plasma sample). Analytical conditions: [Tb3+] = 8.5 × 10−5 mol L−1, [Dano] =1.5 × 10−4 mol L−1, [BSA] = 1 × 10−6 mol L−1, [HSA] = 1 × 10−6 mol L−1, [HSA in plasma sample] = 1 × 10−6 mol L−1, pH = 7.8, λex/λem = 347 nm/545 nm.
Figure 2Effect of pH on the enhanced fluorescence intensity (ΔF%) analytical conditions: [Tb3+]: 1 × 10−4 mol L−1; [Dano]: 1 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1.
Figure 3Effect of concentration of Tris buffer on the enhanced fluorescence intensity (ΔF%) analytical conditions: [Tb3+]: 1 × 10−4 mol L−1; [Dano]: 1 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Figure 4Effect of the Tb3+concentration on the enhanced fluorescence intensity (ΔF%)analytical conditions: [Dano]: 1 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Figure 5Effect of the amount of Dano on the enhanced fluorescence intensity (ΔF%) analytical conditions: [Tb3+]: 8.5 × 10−5 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Effect of the addition order of reagents on the enhanced fluorescence intensity (ΔF%).
| Reagent | Reagent | Reagent | Reagent | ΔF% |
|---|---|---|---|---|
| Tb3+ | Dano | Albumin | Buffer | 46.6 |
| Tb3+ | Dano | Buffer | Albumin | 37.5 |
| Tb3+ | Buffer | Dano | Albumin | 30.9 |
| Tb3+ | Buffer | Albumin | Dano | 36.9 |
| Tb3+ | Albumin | Dano | Buffer | 34.7 |
| Tb3+ | Albumin | Buffer | Dano | 43.5 |
| Dano | Tb3+ | Albumin | Buffer | 39.5 |
| Dano | Tb3+ | Buffer | Albumin | 41.7 |
| Dano | Buffer | Tb3+ | Albumin | 37.3 |
| Dano | Buffer | Albumin | Tb3+ | 44.2 |
| Dano | Albumin | Buffer | Tb3+ | 43.0 |
| Dano | Albumin | Tb3+ | Buffer | 41.3 |
| Buffer | Tb3+ | Dano | Albumin | 26.5 |
| Buffer | Tb3+ | Albumin | Dano | 24.5 |
| Buffer | Albumin | Dano | Tb3+ | 40.7 |
| Buffer | Albumin | Tb3+ | Dano | 33.6 |
| Buffer | Dano | Albumin | Tb3+ | 41.7 |
| Buffer | Dano | Tb3+ | Albumin | 40.1 |
| Albumin | Tb3+ | Dano | Buffer | 37.6 |
| Albumin | Tb3+ | Buffer | Dano | 40.1 |
| Albumin | Dano | Buffer | Tb3+ | 39.5 |
| Albumin | Dano | Tb3+ | Buffer | 43.1 |
| Albumin | Buffer | Tb3+ | Dano | 31.9 |
| Albumin | Buffer | Dano | Tb3+ | 25.8 |
Analytical conditions: [Tb3+]: 8.5 × 10−5 mol L−1; [Dano]: 1.5 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Figure 6Solvent effect on the enhanced fluorescence intensity (ΔF%)Analytical conditions: [Tb3+]: 8.5 × 10−5 mol L−1; [Dano]: 1.5 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Interference effect on the enhanced fluorescence intensity(ΔF%).
| Interfere substance | Concentration of interfere substance (×10−3 mol L−1) | Tolerance ratio (species/HSA) | Chang of ΔIF% |
|---|---|---|---|
| Na+(Cl−) | 5 | 5000 | 1.3 |
| Fe3+ (Cl−) | 0.005 | 5 | −4.2 |
| K+ (CL−) | 3 | 3000 | −2.3 |
| NH4 + (Cl−) | 4.2 | 4200 | −4.7 |
| Saccharose | 1 | 1000 | 3.7 |
| Glycine | 1 | 1000 | −2.4 |
| Mn2+ (Cl−) | 0.05 | 50 | −3.8 |
| ctDNA | 0.00075 | 0.75 | 3.0 |
| Al3+ (Cl−) | 0.005 | 5 | −4.9 |
| Ba2+ (Cl−) | 1.4 | 1400 | −3.4 |
| Ca2+ (Cl−) | 1.15 | 1150 | −4.2 |
| Na+ (CO3 2−) | 1.19 | 1900 | −3.7 |
Analytical conditions: [Tb3+]: 8.5 × 10−5 mol L−1; [Dano]: 1.5 × 10−4 mol L−1; [HSA]: 1 × 10−6 mol L−1; pH = 7.8.
Validation data of the proposed method for quantification of BSA, HSA, and HSA in human plasma.
| Parameters | BSA | HSA | HSA in plasma |
|---|---|---|---|
| Linear range (mol L−1) | 0.2 × 10−6–1.3 × 10−6 | 0.2 × 10−6–1.4 × 10−6 | 0.2 × 10−6–1 × 10−6 |
| Slope | 32.775 | 42.574 | 217.130 |
| Intercept | 3.9446 | 0.2742 | −14.6410 |
| Correlation coefficient | 0.9991 | 0.9990 | 0.9899 |
| Number of data points | 12 | 13 | 9 |
| LOD (mol L−1) | 8.7 × 10−8 | 6.2 × 10−8 | 8.1 × 10−8 |
Intra-assay precision and accuracy of calibration standards.
| Analyte name | Nominal concentration (mol L−1) ( | Found concentration | Precision (RSD%) | Accuracy (RE %) |
|---|---|---|---|---|
| BSA | 0.3 × 10−6 | 0.286 × 10−6 | 2.78 | −4.5 |
| 0.5 × 10−6 | 0.489 × 10−6 | 3.91 | −2.2 | |
| 0.7 × 10−6 | 0.714 × 10−6 | 3.97 | 1.9 | |
| 1.0 × 10−6 | 0.992 × 10−6 | 0.50 | −0.8 | |
| 1.2 × 10−6 | 1.194 × 10−6 | 2.78 | −0.5 | |
|
| ||||
| HSA | 0.3 × 10−6 | 0.308 × 10−6 | 2.85 | 2.9 |
| 0.5 × 10−6 | 0.510 × 10−6 | 3.19 | 2.1 | |
| 0.7 × 10−6 | 0.713 × 10−6 | 3.14 | 1.9 | |
| 1.0 × 10−6 | 0.994 × 10−6 | 1.53 | −0.5 | |
| 1.2 × 10−6 | 1.185 × 10−6 | 1.44 | −1.2 | |
|
| ||||
| HSA in plasma | 0.3 × 10−6 | 0.277 × 10−6 | 4.13 | −7.6 |
| 0.5 × 10−6 | 0.519 × 10−6 | 3.94 | 3.7 | |
| 0.7 × 10−6 | 0.711 × 10−6 | 5.08 | 1.6 | |
| 0.8 × 10−6 | 0.791 × 10−6 | 4.23 | −1.0 | |
| 1.0 × 10−6 | 0.959 × 10−6 | 3.58 | −4.1 | |
Assay precision and accuracy of quality control samples.
| Analyte name | Concentration (mol L−1) | Intra-assay precision (RSD%) | Inter-assay precision (RSD%) | Accuracy (RE%) |
|---|---|---|---|---|
| BSA | 0.3 × 10−6 | 2.62 | 4.55 | −3.9 |
| 0.7 × 10−6 | 4.39 | 1.70 | 1.1 | |
| 1.2 × 10−6 | 4.70 | 3.57 | 2.6 | |
|
| ||||
| HSA | 0.3 × 10−6 | 3.19 | 4.07 | 4.4 |
| 0.7 × 10−6 | 2.79 | 4.62 | 3.1 | |
| 1.2 × 10−6 | 2.00 | 2.60 | −0.4 | |
|
| ||||
| HSA in plasma | 0.3 × 10−6 | 6.44 | 8.08 | −6.3 |
| 0.5 × 10−6 | 4.16 | 4.90 | 1.5 | |
| 0.8 × 10−6 | 3.85 | 3.58 | −2.7 | |
Absolute and mean recoveries for the studied analytes.
| Analyte name | Nominal concentration (mol L−1) ( | Found concentration (mol L−1) ( | Recovery % | Mean recovery % | Precision of recovery (RE%) |
|---|---|---|---|---|---|
| BSA | 0.3 × 10−6 | 0.297 × 10−6 | 99 | 100.7 | −1.0 |
| 0.7 × 10−6 | 0.698 × 10−6 | 99.7 | −0.3 | ||
| 1.2 × 10−6 | 1.240 × 10−6 | 103.3 | 3.3 | ||
|
| |||||
| HSA | 0.3 × 10−6 | 0.294 × 10−6 | 98 | 99.3 | −2.0 |
| 0.7 × 10−6 | 0.705 × 10−6 | 100.7 | 0.70 | ||
| 1.2 × 10−6 | 1.190 × 10−6 | 99.2 | −0.8 | ||
|
| |||||
| HSA in plasma | 0.3 × 10−6 | 0.283 × 10−6 | 94.3 | 95.9 | −5.7 |
| 0.5 × 10−6 | 0.489 × 10−6 | 97.8 | −2.2 | ||
| 0.8 × 10−6 | 0.765 × 10−6 | 95.6 | −4.4 | ||
Stability at refrigerator (4°C) for three days.
| Analyte | Concentration (mol L−1) | After one day at 4°C | After two days at 4°C | After three days at 4°C | |||
|---|---|---|---|---|---|---|---|
| Concentration found (mol L−1) | Accuracy (RE%) | Concentration found (mol L−1) | Accuracy (RE%) | Concentration found (mol L−1) | Accuracy (RE%) | ||
| BSA | 0.3 × 10−6 | 0.224 × 10−6 | −25.3 | 0.216 × 10−6 | −28.1 | 0.210 × 10−6 | −29.9 |
| 0.7 × 10−6 | 0.624 × 10−6 | −10.8 | 0.606 × 10−6 | −13.4 | 0.589 × 10−6 | −15.7 | |
| 1.2 × 10−6 | 1.019 × 10−6 | −15 | 0.983 × 10−6 | −18.1 | 0.962 × 10−6 | −19.8 | |
|
| |||||||
| HSA | 0.3 × 10−6 | 0.26 × 10−6 | −14.1 | 0.251 × 10−6 | −16.1 | 0.249 × 10−6 | −16.8 |
| 0.7 × 10−6 | 0.583 × 10−6 | −16.6 | 0.569 × 10−6 | −18.7 | 0.565 × 10−6 | −19.2 | |
| 1.2 × 10−6 | 0.995 × 10−6 | −17.1 | 0.982 × 10−6 | −18.2 | 0.945 × 10−6 | −21.2 | |
|
| |||||||
| HSA in plasma | 0.3 × 10−6 | 0.217 × 10−6 | −27.5 | 0.216 × 10−6 | −27.9 | 0.214 × 10−6 | −28.8 |
| 0.5 × 10−6 | 0.430 × 10−6 | −13.9 | 0.421 × 10−6 | −15.8 | 0.415 × 10−6 | −16.9 | |
| 0.8 × 10−6 | 0.649 × 10−6 | −18.9 | 0.641 × 10−6 | −19.8 | 0.637 × 10−6 | −20.4 | |
Determinations of HSA in different plasma samples obtained from different human blood samples.
| Sample number | The proposed method | Standard UV spectrophotometry |
|---|---|---|
| Found concentration (×10−4 mol L−1) (RSD%) ( | Found concentration (×10−4 mol L−1) (RSD%) ( | |
| 1 | 6.93 | 6.78 |
| (4.5) | (1.2) | |
|
| ||
| 2 | 6.36 | 6.11 |
| (3.4) | (2.8) | |
|
| ||
| 3 | 6.46 | 6.20 |
| (8.6) | (3.9) | |
|
| ||
| 4 | 6.35 | 6.25 |
| (4.1) | (2.2) | |
|
| ||
| 5 | 6.40 | 6.26 |
| (5.2) | (2.4) | |
|
| ||
| 6 | 6.09 | 6.01 |
| (9.4) | (1.4) | |
|
| ||
| 7 | 6.87 | 6.69 |
| (8.7) | (2.1) | |